Since lysozyme is a small, well-characterized enzyme, we believed that its production by a murine tumor might be studied profitably at the molecular level to gain more insight into the synthesis and secretion of lysosomal enzymes in general. In addition, such a study might shed more light on the possible function of lysozyme other than its bacteriolytic activity.
The previous work described above on the production of lysozyme by the murine tumors did not clearly prove that the oncogenic cells themselves synthesized the lysozyme found in the serum and urine. The same statement is true for patients with monomyelocytic leukemia (3). Thus we first set out to determine the source of the urinary lysozyme. The best way to prove that the tumor cells indeed synthesize large quantities of lysozyme would be to establish a permanent line from the tumor cells, to clone the cells, and to show that the cloned tumor cells produced lysozyme in vitro. We were unable to establish a permanent line from the cells of the GPC-II tumor, a transplantable reticulum cell sarcoma, type A. However, Scharff and his collaborators (personal communication) established a tissue culture line from the WEHI-3 tumor described by Warner et al. (4) . Unfortunately, they found that both the tumor and the cell line were making small amounts of lysozyme.
We turned to other techniques to ascertain the source of lysozyme in mice with the GPC-ll tumor. Cell suspensions of the tumor were centrifuged in colloidal silica-sol gradients, and the fractions collected from the gradients were analyzed for lysozyme and oncogenic cells. The results indicated that oncogenic cells did not possess lysozyme activity and that cells containing lysozyme did not produce tumors in the mice. Morphologic and functional observations indicated that the cells producing lysozyme were macro phages associated with the tumor.
Evidence is increasing that tumor-associated macrophages have an in vivo relevance as effector cells in the cell-mediated mechanisms of tumor damage. In this report, we call attention to the diagnostic importance of the lysozyme content in the urine of the mice with the GPC-II tumor as an expression of the activity and number of cytotoxic macrophages in the tumor. Our results suggest that the lysozyme content in the urine of tumorbearing mice represents a simple in vitro assay that accurately reflects the effector functions in vivo of a single class of cells in the host-tumor system. The lysozyme assay described by Schweiger and Gold (11) and used by us in the present study is more sensitive and more easily quantitated than the assays previously used to measure urinary lysozymes. Thus it makes lysozyme analysis more readily applicable to clinical situations. Center, Stanford, CaliL). At 4 weeks of age, they were given ip injections of 0.2 ml tumor cell suspension (12) . After 2-5 months, they developed clinical signs of tumors. At that time the mice were killed, and the tumors were used in experiments or transplanted into other mice.
MATERIALS AND METHODS

Animals and tumors.-(NZB
GPC-11 cell suspensions.-Single cell suspensions were made by mixing the tumor tissue in Hanks' buffer containing 20 U heparin/ml and 100 U penicillin/ml. The tumor tissue, containing no visible regions of necrosis or hemorrhage, was minced in the buffer into fragments of about 2x2 cm. The tissue was then ground through an 80-mesh steel gauze (13) . Cells were suspended in Hanks' buffer and centrifuged two or three times at 600 rpm for 10 minutes to separate debris. All procedures were performed at 4° C to minimize adverse effects on cell viability (14) . Viability was determined by phasecontrast microscopy and by the ability of intact cells to incorporate p5S]methionine.
GPC-ll cell separation. -The colloidal silica-sol Ludox HS (40% wt/wt in deionized water, density 1.303 g/ml) was purchased from du Pont de Nemours & Co. Physical and chemical dat~ were reported in (15) (16) (17) . About 10-50 X 10 6 cells were resuspended in 2 ml Hanks' buffer stabilized with 2% dextran. The gradients were formed by centrifugation of the cell suspension on the gradient medium for 20 minutes at 15,000 rpm in a Sorvall centrifuge with an SS34 rotor (Dupont Instruments: Sorvall, San Mateo, Calif.). All operations were done at 4° C to reduce cell aggregation. After centrifugation, O.5-mI fractions were removed from the bottom of the gradients. Each fraction was diluted ten times with cold buffer and washed several times to remove silica and polymers. To measure lysozyme activity (11) , protein concentration (18) , and incorporation of radioactive amino acids in each fraction, the cells were resuspended in 0.5 ml distiIIed water and vibrated at 0° C for 30 seconds at a low setting in a Biosonik III sonicator (Bronwill, Rochester, N.Y.).
Macrophage preparations.-GPC-ll cell suspensions were made as described. The G PC-II-associated macrophages were isolated from the cell suspensions with the use of functional criteria as described by Evans (19) . Control macro phages not associated with the tumor were obtained by lavage of the peritoneal cavity of nor-J NATL CANCER INST mal (NZB X BALB/c)FJ mice 5 days after stimulation by ip injection of 5 mg glycogen in saline buffer. Peritoneal cell suspensions were given the same treatment as that given GPC-Il cell suspensions. Macrophage monolayers were cultured routinely in complete Dulbecco's medium supplemented with 5% inactivated FCS and incubated at 37° C in the presence of 5% carbon dioxide.
When in vitro labeling was required, 2-day-old macrophage cultures were first washed three times with buffer, labeled with 10 p.Ci/ml of a mixture of [14C]aspartic acid, asparagine, alanine, and arginine in Dulbecco's medium with a 1/20 concentration of amino acids, and supplemented with 5% inactivated FCS. After 5 hours' incubation, the medium was discarded, and the cultures were washed three times with buffer and incubated 5 days in complete Dulbecco's medium with 5% inactivated FCS (20) .
Lysozyme assay . -The amount of lysozyme activity in the urine and in the cells was determined by the release of [3H]diaminopimelic acid, which had been incorporated into Escherichia coli K12-W7 (a lysine-diaminopimelic acid-requiring strain) cell walls and fixed to filter paper discs prepared as described by Schweiger and Gold (11) . Two microliters of urine, or 25-p.l portions of each of the sonically vibrated cell fractions obtained from the Ludox HS gradients, were incubated at 37° C for 2 hours with 1 ml of 100 mM ammonium acetate, 0.4 mM EDTA, 100 p.g chloramphenicol/ml, and a radioactive disc. After incubation, 100 JLI was removed and added to 10 ml Bray's solution. The amount of radioactivity was determined in a liquid scintillation spectrophotometer at an efficiency of 30% for tritium.
Purification of mouse urinary lysozyme.-GPC-ll lysozyme was purified from the urine of the affected mice by ion-exchange chromatography on carboxymethyl cellulose, as outlined by Riblet and Herzenberg (5). About 160 mg lysozyme was obtained after purification from 80 ml urine from mice with the GPC-l1 tumor. The average concentration in the urine was thus at least 2 mg/ml, the same range as that reported in (5). The main peak of lysozyme gave one major stained band when the protein was denatured and subjected to electrophoresis on SDS-polyacrylamide gels. A single precipitin line was formed upon double diffusion on OuchterIony plates, which indicated the presence of only one antigenic component in the protein preparation.
Purification of lysozyme from supernatant of macrophage tissue cultures.-The supernatant from the labeled macrophage tissue culture was collected after 5 days' incubation and centrifuged at 1,500 rpm for 15 minutes to separate cells and debris. The supernatant was then immediately lyophilized. The lyophilized material was resuspended in 1 ml of 50 mM Tris HCl (pH 7.4),1 mM magnesium acetate, and 0.6 mM dithiothreitol and was passed through a G-50 Sephadex column. The presence of lysozyme in the eluate was determined by the antibody precipitation reaction with the use of an antiserum from rabbits immunized against the GPC-ll lysozyme. The specificity of this precipitation was verified by electrophoresis of the radioactive precipitate on SDS gels and subsequent quantification of the radioactive bands by a double-beam microdensitometer, model MKlIIC, VOL. 57, NO. 4, OCTOBER 1976 from Joyce, Loebl and Co., Burlington, Massachusetts.
Immunologic analysis.-The immunoprecipitation method of Palmiter et al. (21) was used to detect lysozyme released into the supernatant of the tissue culture of the macrophages isolated from the GPC-II tumors. The rabbit antisera were prepared as described by Prager and Wilson (22) .
Preparation and electrophoresis of samples.-Samples obtained from the supernatant of labeled macrophage tissue cultures were processed as described by Hopper et al. (23) . SDS slab gel electrophoresis of proteins was done as outlined by Studier (24) .
Electron microscopy.-The tumor was sliced into small blocks and fixed in 15% glutaraldehyde in 0.11 M symcollidine at room temperature for 1-2 hours. The tissue was then rinsed in buffer, post fixed in 1 % OS04 in symcollidine for 1 hour, stained en bloc with 1.5% aqueous uranyl acetate for 15 minutes, dehydrated in ethanol, and embedded in Epon (25) . Sections were stained with uranyl acetate and poststained with lead citrate (26) .
RESULTS
Analysis of GPC-11 Cell Separation on Ludox HS Gradients
The hypothesis that different cell types were present in vivo in the GPC-ll tumor was investigated by separation of tumor cell suspensions on 20% Ludox HS gra- 
dients, followed by analysis of each fraction for lysozyme and oncogenic activity. Three different concentrations of cells were fractionated on a 20% concentration of Ludox HS. The cell migration on the gradients was characteristic of the colloidal silica-sol concentration and did not depend on the cell concentrations (text- fig.  I ). We tested the loss of cell viability due to Ludox treatment by measuring the ability of the cells to incorporate [35S]methionine before and after fractionation (table 1) . Apparently about 40% of the entire GPC-Il cell population was inactivated immediately after the treatment.
After separation, a small portion of the cells in each fraction was lysed for the lysozyme assay (11) . Fractions were then pooled in three amounts: a) fractions from 1 to 10 with lysozyme activity (gradient A), b) fractions from 11 to 20 (gradient B), and c) fractions from 21 to 32 without lysozyme activity (gradient C), as shown in textfigure 1. As a test for their oncogenicity, the three pooled fractions were washed several times, resuspended in buffer, and injected ip into three groups of 6 normal (NZB X BALB/c)F, mice. The controls were a fourth group of 6 mice given ip injections of the same number of GPC-I I cells not previously fractionated on a Ludox gradient. Two months after the treatment, the urine of the mice receiving the injections was assayed for lysozyme activity. We chose to assay for urinary Iyso- ...J ...J 500 ~ TEXT-FIGURE I.-After mechanical disruption of the tumor tissue, three GPC-II cell concentrations, lOx 10 6 (gradient A), 25x 10 6 (gradient B), and 50x 10 6 (gradient C). were resuspended in 2 ml Hanks' buffer and centrifuged on 14 ml density gradients generated in 20% Ludox HS, as described in "Materials and Methods." The gradients were collected in 0.5-ml fractions. Each fraction was analyzed for lysozyme activity (0---0) and for protein content by the method of Lowry et al. (I8) (--) . A total of 12x 10 6 stimulated macrophages (gradient D), obtained by lavage of the peritoneal cavities of normal (NZB x BALB/c)F, mice, was fractionated and tested for lysozyme activity and protein content under the same conditions as those used for the GPC-II cell suspensions. The density gradients generated in the Ludox HS during centrifugation are reported in gradient D (e---e). M and B denote the meniscus and the bottom of the centrifuge tube, respectively. Shaded area indicates a solidifIed mass. Cell viability in each fraction was measured by the incorporation of [35S1methionine/ /Lg protein (a---a) (gradient C). Cells were resuspended in 0.5 ml Dulbecco's medium with 1/20 amino acids and supplemented with 5% inactivated FCS. After 30 minutes' preincubation at 37° C in a shaking Dubnoff bath (operating at 100 cycles/min), the cell suspension was exposed to 100 /LCi [35S]methionine/ml. The cells were incubated for 2 hr; we terminated this process by diluting the cells with a 50-fold volume of cold isotonic buffer. Cells were washed several times and then fractionated as usual in a 20% Ludox HS gradient. Radioactivity in each fraction was determined by TCA precipitation of the cell Iysates. Sedimentation is from left to right. 6 cells were fractionated on a 20% Ludox HS gradient. After fractionation, cells were pooled and washed several times to remove silica and then plated in a plastic dish (Falcon Plastics, Oxnard, Calif.) at a density of2xl0 5 cells/cm 2 • Cells were pre incubated in Dulbecco's medium lacking methionine and supplemented with 5% FCS for 30 min at 37" C in the presence of carbon dioxide. Then cells were labeled with 100 /-lCi [35S1methionine/ml. We incubated the cells for 6 hr and terminated this process by ~ashing the cells with a 50-fold volume of cold buffer. TCA precipitatIon was used to determine radioactivity in the culture medium after the unattached cells were pelleted (a), in the pellet of the cells in suspension in the culture medium after centrifugation (b) , and in the adhering cells (e). As a control, an equal amount of cells not previously fractionated on the Ludox HS gradients was tested under the same conditions. zyme 2 months after inoculating the mice with the GPC-II c~ll fractions to avoid measuring a transient Iysozymuna probably due to some aspecific inflammation immediately after tumor transplantation (unpublished results). The lysozyme was detectable only in the urine of ~)I~e t~st group of animals (mice that had been given injectIOns of cells containing little or no lysozyme activity) that was pooled from fractions 10 to 20 separated on the gradients (table 2) . These animals were the only group, in addition to the control group, to develop the typical GPC-II tumor; they had a tumor incidence of ~O~%: The clinical signs of tumor in the mice given injectIOns of the Ludox HS-fractionated oncogenic cells appeared 1-2 months later than did those in the control mice given injections of GPC-II unfractionated cells. The delay was probably due to a reduction in the number of active tumor cells. Indeed, the data in table I indicated that cell viability was adversely affected by centrifugation in the Ludox HS gradient.
The separation data indicated that at least two cell populations were present in the GPC-II tumors: one with lysozyme activity found in fractions from I to 10 and one with oncogenic activity found in fractions from II to 20. The last part of the gradients, from fraction 21 to 32, consisted mostly of debris as indicated by the low specific activity of the [35S]methionine incorporated (text- fig. I , gradient C).
Identification of Cells Producing Lysozyme
The cell fraction with lysozyme activity represented a considerable percent (13-20%) of the total GPC-II cell J NATL CANCER INST population separated on the 20% Ludox HS gradient. The lysozyme assay (11) indicated that the content of the enzyme in this fraction was 3.5% of the total cell protein.
To identify the type of cell producing lysozyme and its role in the tumor, morphologic and functional experiments were done in vivo and in vitro. Electron micrographs indicated that the GPC-II tumor tissue was represented in vivo by a cell population heterogeneous in size and morphology ( fig. 1) . One of these types was morphologically characterized by infolding of the plasma membrane ( fig. 2) . It has been observed that !nterdi~itation of the cell surface is common during interactIOn of macrophages with target cells both in vivo (27) and in vitro (28). It is also well known that macrophages can synthesize lysosomal enzymes, including lysozyme, whose production is often regarded as a cytochemical marker (7) and as a useful measure of macrophage number (20) . We observed that peritoneal macrophages from normal (NZB X BALB/c)F 1 mice, when centrifuged on a 20% Ludox HS gradient, had the same migration pattern as the cells with lysozyme activity in the GPC-ll cell suspension (text- fig. I, gradient D) . Therefore, the cells producing lysozyme in the GPC-IIaffected mice might be macro phages associated with the tumors. To verify this hypothesis, we isolated macrophages from GPC-ll cell suspensions using as functional criteria their rapid adherence to glass and their resistance to detachment by trypsinization (19) . The above criteria were employed to isolate only the macrophage population from the total GPC-II cell suspensions. These techniques, rather than the Ludox HS gradient separation, were utilized to avoid the adverse effect of the silica on cell viability which we observed in the previous experiments. The biosynthesis and secretion of lysozyme by these cells during culture were confirmed by the identification of 14C-labeled lysozyme in the cellfree culture fluid from cells previously incubated with radioactive amino acids. The culture medium was passed through a G-50 Sephadex column to separate proteins on the basis of their molecular weight. Fractions from the column were tested by specific immunoprecipitation with antilysozyme serum. Immunoprecipitates appeared in one major region coincident with the retarded proteins of low molecular weight. Radioactivity in the immunoprecipitates represented 95% of the ~CA-insoluble radioactivity in the corresponding fractIOns. SDS-polyacrylamide gel electrophoresis of the immunoprecipitates from the peak of proteins of low molecular weight revealed a single major radioactive band at 14,000 (mol wt) which underwent electrophoresis at the same time as the lysozyme purified from the urine of the animals with the GPC-II tumor and as the lysozyme purified by the same technique from a culture of peritoneal macrophages from normal (NZB X BALB/c)FJ mice used as controls ( fig. 3 ). Densitometric analysis of the radioautograms revealed that the lysozyme represented at least 65% of the total radioactive immunoprecipitates. In mice with the GPC-II tumor, the macrophage enzyme thus resembled in antigenicity and size the lysozyme released in the urine and was clearly synthesized and secreted in vitro.
The above experiments provided strong evidence that the presence of lysozyme in mice with GPC-II tumor was an expression of the tumor-associated macrophage activity, since the enzyme is a cell-specific product. Further experiments are in progress to explore the usefulness of the lysozyme assay of urine from animals affected by several other types of tumor. Preliminary results have confirmed the validity of the assay. It appears that the lysozyme is specifically present in the urine only when macro phages are actively present in the tumor, probably participating in host defense. We detected lysozyme activity (1.35 mg/ml) in the urine of C57BL/Ks mice with Sarcoma lone week after inoculation, when macrophages represent 20-25% of the Sarcoma I cell composition (29) ; however, we did not detect lysozyme activity in the urine of the same animals after they had rejected the tumor. On the other hand, little lysozyme activity (0.2 mg/ml) was found in the urine of the nonresistant A/] mice given injections of Sarcoma I under the same conditions.
DISCUSSION
Our major conclusion is that the lysozyme associated with the transplantable GPC-II tumor is due to the presence of macrophages in the tumor and not to lysozyme synthesis in the tumor cells themselves (5) . The evidence for this conclusion is based on the separation on Ludox gradients of nononcogenic, lysozyme-containing cells from oncogenic cells lacking lysozyme. In the following discussion, we assume that the macro phages are host derived, although it cannot yet be ruled out that they are tumor derived, but lack further proliferative capacity. Studies with Sarcoma I in C57BL!Ks and A/] mice support the conclusion that the tumor-associated, lysozyme-containing cells are host macro phages , since they are present only in the C57BL/Ks mice during growth and rejection of the tumor. Nonresistant A/] mice, given an injection of the same tumor, do not develop extensive lysozymuria despite the more massive growth of the tumor (unpublished results). We are studying other tumor systems in which the distinction between host and tumor origin of the lysozyme-containing cells might be made more easily than in the GPC-II system studied here.
The participation of either "armed" (30) (31) (32) or "activated" (33-37) macrophages as effector cells in the inhibition and destruction of tumor target cells has long been suggested by evidence from in vitro and in vivo studies (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) . Present data on macrophage-induced VOL. 57, NO.4, OCTOBER 1976 cytotoxicity do not reveal the precise mechanism of damage to target cells. It has been suggested that close cell apposition is a prerequisite for target cell damage (33, 37) , and electron microscopic studies have shown juxtaposition of interacting cells (28, 40) . Sellin et al. (41) , incubating target cells with macrophages labeled with fluorescein propionate, showed a passage of the compound from macrophage to the target cells during the cytotoxic reaction. The data suggest that molecules pass from one cell to another. Some of these molecules may be the mediators of target cell destruction. Hibbs (33) used phase-contrast microscopy and the lysosomal marker to show that lysosomes were directly transferred from activated macrophage into the cytoplasm of susceptible target cells that subsequently underwent heterolysis. The reaction was inhibited by agents that prevented the exocytosis of macrophage lysosomes (hydrocortisone) or interfered with the action of lysosomal enzymes (trypan blue). Such a cytolytic process presumably involves membrane fusion of effector and target cells. However, Currie and Basham (42) recently reported lysis of malignant rat cells by the supernatant cellfree media from endotoxin-activated rat macrophages, which suggests selective recognition of characteristic features of the malignant cell surface by a macrophage product, presumably enzymes.
Osserman et al. (9) used lysozyme concentrations within the range that might be achieved in vivo at sites where macrophages interact with target cells. They obtained morphologic evidence in vitro of an effect by the homologous lysozyme on the membrane of transformed cells. They observed no effect with nontransformed cells. Thus the authors suggested that lysozyme is an important mediator of some of the non phagocytic functions of macrophage, possibly including functions related to surveillance of membrane abnormality in neoplastic transformations. It was not shown whether this effect required enzymatic activity of the lysozyme. Although this hypothesis deserves further investigation, the functions of lysozyme in mammalian physiology, distinct from its antibacterial activity, are still unknown. Unfortunately, in studies on macrophage content in tumors and the role of macrophages as effector cells in host defense, a parallel lysozyme analysis of serum, urine, stools, and intestinal contents was not done in the affected animals. It might be expected tht the lysozyme content in affected animals will be higher than that in normal animals, proportional to the number of macrophages infiltrating the tumor.
In our studies, we do not yet know whether the lysozyme in the urine of mice with GPC-II tumor and Sarcoma I is released' in vivo directly by the activated macrophages during cytotoxic activity, by the target cells after they undergo cytolysis, or by decaying macrophages. We purified the lysozyme from the supernatant of cultures of activated macrophage isolated from the GPC-ll tumor, but a recent study revealed that lysozyme is continuously released from mouse peritoneal macro phages in tissue culture independent of phagocytosis or stimulation (20) . It has also been reported that macrophages can selectively release lysosomal enzymes under various conditions, i.e., exposure to polysaccha-ride and peptidoglycan (43) , cytochalasin B (44), E. coli (45) , and products released by stimulated lymphocytes (46) . Electron microscopic studies reveal a dramatic increase in the number of Iysosomes over the first few hours after macrophages and target cells come into contact (40) .
The above observations and our results suggest a selective secretion of lysosomal enzymes in neoplasia by activated macrophages, indicating the physiologic importance of the enzyme as an auxiliary mechanism in host defense against cancer. Indeed, lysozyme has a low toxicity on normal cells in vitro, and large amounts of homologous lysozyme (up to 5 mg/g-I body wt administered iv or ip daily for several wk) are well tolerated by mice and rats (9) . During the cytotoxic activity of macrophage in neoplasia, the lysozyme might disarrange the surface of the transformed cells when effector and target cells are in contact and thus facilitate the diffusion of cytostatic and cytolytic agents into the tumor cells. This hypothesis seems consistent with the findings of other authors who suggested that the critical modification underlying the destruction of tumorigenic cells by activated macrophage is local or general membrane destabilization in both cells, which favors focal and temporary membrane fusion (33, 47, 48) . At present, our observation, that the presence of lysozyme in the urine of tumor-bearing animals is an expression of the cytotoxicity of activated macrophages, may be of clinical value in detecting the specificity of the host's defense mechanisms. Purified lysozyme from urine of mice with the GPC-I I tumor was used as a control (e).
